Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Replicel Life Sciences Inc V.RP

Alternate Symbol(s):  REPCF

RepliCel Life Sciences Inc. is a Canada-based regenerative medicine company. The Company is focused on developing cell therapies for aesthetic and orthopedic conditions, including aging/sun-damaged skin, pattern baldness, and chronic tendon degeneration. The Company’s cell therapy product pipeline is comprised of RCT-01 for tendon repair, RCS-01 for skin rejuvenation, and RCH-01 for hair restoration. RCH-01 is an autologous cell therapy utilizing dermal sheath cup (DSC) cells isolated from the hair follicle to treat androgenetic alopecia. RCS-01 is an autologous cell therapy utilizing non-bulbar dermal sheath (NBDS) cells, a type of fibroblast cell isolated from the hair follicle to repair and regenerate tissue. RCT-01 provides a source of collagen expressing cells to the site of injury, addressing the underlying cause of tendinosis. It has also developed an injection device, DermaPrecise, which improves the administration of its cell therapy products and certain other injectables.


TSXV:RP - Post by User

Comment by Ingiboyon Mar 28, 2024 12:21pm
81 Views
Post# 35958238

RE:RE:Buyout

RE:RE:BuyoutBellend2,

I hope this is not a "done deal".   I am sure that Andrew contacted all major shareholders to see if they would vote yes on this proposal before launching it.  That is what scares me and supports your theory that it is a done deal.
On the other hand we need to remember he needs 66 2/3% approval to pull this off and that may be tough.
If it is rejected and he truly wants to control the company he may consider the buyout option.  If this is the case it will be an interesting calculation to see what the buyout offer is.

On the other side for those that are hoping a buyout occurs, whatever the price many will be unhappy.  We all have different average share prices and at a minimum would like to get our investment back.  Many of us bought shares years ago with higher averages while others may be between $.10 - $.20.



 
<< Previous
Bullboard Posts
Next >>